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Poster Session I S201survival was 35months (95%CI: 22 – 43months). There were nodose
limiting toxicities. Grade 3 toxicities were similar to those observed
withhigh dosemelphalan alone.The dose of bortezomib administered
after melphalanwas safely escalated to 1.3mg/m2. FA/BRCA pathway
gene expression was evaluated with quantitative RT-PCR (i) at base-
line, (ii) after 1 dose of bortezomib, and (iii) after the 2 pre-transplant
cycles of bortezomib in 17 patients (15 had transplants). After the first
dose of bortezomib, there was a statistically significant decreased ex-
pression of FANCD1 (P 5 0.072) and FANCF (P 5 0.0458) as well
as a suggestion of decreased expression of 4 other FA/BRCA genes.
We conclude that bortezomib can be safely combined with high
dose melphalan and with no added toxicity. The combination of bor-
tezomib and melphalan conditioning warrants further evaluation
with a phase 2 study design in a broader myeloma population.129
PROLIFERATIVE CAPACITY AND CELLULAR COMPOSITION OF APHERE-
SIS PRODUCTS COLLECTED FROM PATIENTS MOBILIZED SEQUENTIALLY
WITH NEUPOGEN THEN NEUPOGEN PLUS PLERIXAFOR
Siebenlist, R., Sawyer, S., Taylor, R., Treisman, J., Garlie, N. Aurora St.
Luke’s Medical Center, Milwaukee, WI
Background: Mobilization with Neupogen plus Plerixafor versus
Neupogen alone yields a product with more CD341 stem cells,
thus reducing the overall time and cost for stem cell collections.
Since the mechanism of action is different for these two mobilizing
agents, we determined whether or not there are differences in the
proliferative potential and cellular composition of the apheresis
products collected after mobilization.
Methods:Wecompared apheresis products frompatientsmobilized
with both stem cell regimens sequentially (Neupogen only, then
Neupogen plus Plerixafor). Stem cells (CD45/34) were enumerated
prior to cryopreservation by flow cytometry.The proliferative capac-
ity of thawed apheresis products was evaluated using a HALO assay
(Hemogenix), which utilizes luminescence to measure the prolifera-
tive capacity of cells by quantifyingATP concentrations.The cellular
composition of the thawed samples was evaluated by flow cytometry
for various lineage markers and T-cell differentiation markers.
Results: The proliferative capacity of apheresis products collected
after mobilization with Neupogen was lower compared to products
collected after Neupogen plus Plerixafor mobilization (p\ 0.05).
This correlates with the CD34 content in the products, which tends
to be lower in products mobilized with Neupogen (0.2560.18%)
versus Neupogen plus Plerixafor (0.3560.27%), but the difference
is not significant (p 5 0.23). However, ATP levels calculated per
stem cell were similar (P 5 0.34, n 5 15 patients) between products
mobilized with the two regimens. Phenotypic analyses of the prod-
ucts from 3 patients each mobilized with both regimens were
performed. T-helper cells (CD4) were higher (32% vs. 24%, P 5
0.02) in the apheresis productsmobilizedwithNeupogen only versus
Neupogen plus Plerixafor. There were no other significant differ-
ences in phenotypic markers, however, there was a trend toward
a lower percentage of lin1dimHLA-DR1CD11c1 dendritic cells
(p5 0.08) in the apheresis productsmobilizedwithNeupogen versus
Neupogen plus Plerixafor. Evaluation of additional samples will
determine if this trend is significant.Table 1. Outcomes of Autologous PBSC Mobilization with G-CSF a
with or without Lenalidomide (LEN)
L
All (n517) #4
Day 1 CD34+ cells/mL, median (range) 75.83 (12.46-167.37) 73.57
Day 1 CD34+ cell yield (x 106/kg), median (range) 4.96 (1.43-17.11) 6.87
Total CD34+ cell yield (x 106/kg), median (range) 7.22 (2.32-17.11) 6.87
CD34+ cell yield $6  106/kg, no. of patients (%)
Day 1 8 (47.1) 5
All days 11 (64.7) 5
*All LEN-treated patients vs. no LEN;
**2-sided Mann-Whitney U test;
†2-sided Fisher exact testConclusion: Although the mechanisms of action of Neupogen and
Plerixafor are different, the proliferative capacity of the stem cells
generated after treatment with Neupogen alone versus Neupogen
plus Plerixafor is similar. However, the cellular composition of the
products is different and may affect the quality of the stem cell graft.130
INITIAL MOBILIZATION OF AUTOLOGOUS PERIPHERAL BLOOD STEM
CELLSWITH GRANULOCYTE COLONY-STIMULATING FACTOR AND PLER-
IXAFOR IN PATIENTSWITHMULTIPLE MYELOMA: A PROSPECTIVE COM-
PARISON IN LENALIDOMIDE- AND NON-LENALIDOMIDE-TREATED
PATIENTS
Anwer, F., Green, M.R., Yeager, A.M. Arizona Cancer Center, Univer-
sity of Arizona, Tucson, AZ
Background: The use of lenalidomide (LEN) in patients (pts) with
multiple myeloma (MM) is associated with impaired mobilization
and collection of autologous peripheral blood stem cells (PBSCs) af-
ter granulocyte colony-stimulating factor (G-CSF) or chemotherapy
plus G-CSF. The combination of G-CSF and plerixafor (PLX; Mo-
zobil) is an evolving strategy for PBSC mobilization, but effects of
LEN exposure on mobilization with G-CSF and PLX have not been
extensively evaluated. This single-center prospective study com-
pared results of initial PBSC mobilization with G-CSF and PLX
in MM pts whose primary therapy did or did not include LEN.
Patients andMethods:Of 23 consecutive pts, 17 had received ame-
dian of 5 (range 2-12) 21-day cycles of LEN; 6 had not received
LEN. All pts received G-CSF (10 mg/kg/day sq  4 days) and
PLX (0.24 mg/kg sq on the evening of 4th day of G-CSF), with first
apheresis (3 blood volume) at amedian of 16.6 (range 15.3-17.5) hr
after PLX injection. Pts who collected\ 6  106/kg CD341 cells
with first apheresis received both G-CSF and PLX that evening
and underwent a second day of apheresis. Mobilization failure was
defined as total collection of\2 x106/kg CD341 cells; optimal col-
lection was defined as $ 6  106/kg CD341 cells.
Results: All 17 LEN-treated pts collected $ 2  106/kg CD341
cells (median 7.22  106/kg; range 2.32-17.11  106/kg) with a me-
dian of 2 (range 1-3) aphereses. Eleven pts (64.7%) collected $ 6 
106/ kgCD341 cells, 8 with 1 apheresis. Five of 8 pts who received#
4 cycles of LEN collected$ 6 106/ kg CD341 cells with 1 apher-
esis, compared with 3 of 9 pts who received. 4 cycles (P5 0.35). All
6 pts without LEN collected $ 6  106/kg CD341 cells (median
13.67  106/kg; range 6.56-22.66  106/kg) with a median of 1
(range 1-2) apheresis. The LEN group had lower median day 1 pe-
ripheral blood CD341 cell levels (75.83 vs. 135.00/mL; P 5 0.052),
day 1 apheresis yields (4.96 vs. 13.67  106/kg CD341 cells; P 5
0.030) and total apheresis yields (7.22 vs. 13.67  106/kg CD341
cells; P 5 0.024) than the non-LEN group.
Conclusions: Initial mobilization with G-CSF and PLX is effective
in LEN-treated MM pts, with a trend to more robust day 1 PBSC
collections after# 4 cycles of LEN. In this prospective comparison,
however, the outcomes in LEN-treated pts were inferior to those in
pts without LEN exposure. Additional studies are needed to delin-
eate the influence of LEN on mobilization of PBSCs with G-CSF
and PLX.nd Plerixafor in Multiple Myeloma Patients Previously Treated
EN-treated
cycles (n58) >4 cycles (n59) No LEN (n56) P*
(12.46-167.37) 50.68 (26.24-163.08) 135.00 (52.56-222.84) 0.052**
(1.43-17.11) 4.14 (2.26-14.19) 13.67 (4.16-22.66) 0.030**
(2.32-17.11) 6.20 (4.15-14.19) 13.67 (6.56-22.66) 0.024**
(62.5) 3 (33.3) 5 (83.3) 0.18†
(62.5) 6 (66.7) 6 (100) 0.14†
